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A B S T R A C T
Diabetes mellitus is challenging in the context of the COVID-19 pandemic. The prevalence of diabetes
patients hospitalized in intensive care units for COVID-19 is two- to threefold higher, and the mortality
rate at least double, than that of non-diabetes patients. As the population with diabetes is highly
heterogeneous, it is of major interest to determine the risk factors of progression to a more serious life-
threatening COVID-19 infection. This brief review discusses the main findings of CORONADO, a
prospective observational study in France that specifically addressed this issue as well as related
observations from other countries, mainly China and the US. Some prognostic factors beyond old age
have been identified: for example, an increased body mass index is a major risk factor for requiring
respiratory assistance. Indeed, obesity combines several risk factors, including impaired respiratory
mechanics, the presence of other comorbidities and inappropriate inflammatory responses, partly due to
ectopic fat deposits. While previous diabetic microvascular (renal) and macrovascular complications
also increase risk of death, the quality of past glucose control had no independent influence on
hospitalized diabetes patient outcomes, but whether the quality of glucose control might modulate risk
of COVID-19 in non-hospitalized diabetes patients is still unknown. In addition, no negative signs
regarding the use of RAAS blockers and DPP-4 inhibitors and outcomes of COVID-19 could be identified.
Hyperglycaemia at the time of hospital admission is associated with poor outcomes, but it may simply be
considered a marker of severity of the infection. Thus, the impact of glucose control during
hospitalization on outcomes related to COVID-19, which was not investigated in the CORONADO
study, is certainly deserving of specific investigation.




The prevalence of diabetes in patients with COVID-19
(Coronavirus Disease 2019), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection, has varied across
countries, ranging from 5–20% in China, 17% in Lombardy in Italy
and 33% in the US [1–4]. Diabetes can modulate host–viral
interactions and host–immune responses via several mechanisms
that could also lead to poorer outcomes (see Muniyappa and Gubbi
for a review [5]). Of major clinical importance, all studies have so
far reported a two- to threefold higher prevalence of diabetes in
patients with severe infections requiring admission to intensive
care units (ICU) and invasive ventilation compared with those with* Corresponding author.
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patients with diabetes (Table 1) [6–14].
However, diabetes patients constitute a highly heterogeneous
population in terms of type of diabetes, duration of disease, quality
of glucose control, presence of diabetic complications, interference
of comorbidities such as obesity and hypertension, and type of
glucose-lowering therapy, among others. Which of these different
factors could be playing a significant role in the final prognosis of
diabetes patients hospitalized because of COVID-19 is virtually
unknown in the absence of large prospective studies to address this
crucial question.
In fact, the available data in the literature are rather scarce, and
some reports have only considered prognostic factors based on
theoretical grounds [15]. One small retrospective single-centre
observational study in China analyzed the clinical characteristics
and outcomes of 48 severe COVID-19 patients with diabetes [16],
and found that survivors of COVID-19 with diabetes did not differ patients with diabetes hospitalized for COVID-19: Findings from
20), https://doi.org/10.1016/j.diabet.2020.05.008
Table 1
Risk of poor clinical outcomes and death in diabetes patients with COVID-19 infection.
References Studies (n) (n of patients) Poor composite outcomes HR/OR (95% CI) Death HR/OR (95%CI)% CI)
Observational studies
Zhou et al., 2020 [6] One, Wuhan, China (191) NA 2.85 (1.35–6.05)
Guan et al., 2020 [7] One, nationwide, China (1500) 1.59 (1.03–2.45)a NA
Meta-analyses
Li et al., 2020 [8] Three (1278) 2.21 (0.88–5.57)b NA
Roncon et al., 2020 [9] Four (1380/354) 2.79 (1.85–4.22)b 3.21 (1.82–5.64)
Fadini et al., 2020 [10] Six, China (1687) 2.26 (1.47–3.49)c NA
Yang et al., 2020 [11] Seven (1576) 2.09 (0.89–4.82)c NA
Zheng et al., 2020 [12] 11 (2570) 3.68 (2.68–5.03)d NA
Huang et al., 2020 [13] 30 (6452) 2.38 (1.88–3.03)e 2.12 (1.44–3.11)
Wang et al., 2020 [14] 31 (6104) 2.61 (2.05–3.33)c NA
HR: hazard ratio; OR: odds ratio; CI: confidence interval; NA: not available
a Intensive care unit (ICU), ventilation or death.
b ICU admission.
c severe COVID-19 infection.
d mortality/critical events.
e mortality, severe COVID-19 infection, acute respiratory distress syndrome (ARDS), need for ICU care, disease progression.
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associated comorbidities, including hypertension, cardiovascular
disease (CVD) and chronic pulmonary disease. Indeed, survival was
independent of overall glycaemic control, as assessed by glycated
haemoglobin (HbA1c) on hospitalization. However, given the very
small number of patients, this analysis has to be interpreted with
caution. In the largest series of 5700 patients hospitalized with
COVID-19 in New York City in the US, it was only mentioned in
passing that, of the patients who died, those with diabetes were
more likely to have received invasive mechanical ventilation or
care in the ICU compared with those without diabetes, with no
further information provided regarding the characteristics of those
diabetes patients [17].
One key question is whether diabetes is a risk factor for COVID-
19 infection and poorer outcomes because of the deleterious role of
hyperglycaemia on immune responses and defence against
infections [18], the multiple complications associated with
diabetes, especially CVD and/or renal disorders, and the comorbi-
dities frequently encountered, such as obesity, hypertension and
obstructive sleep apnoea, in the type 2 diabetes (T2D) patient
population [19]. Furthermore, the potential interference of certain
medications frequently prescribed for diabetes patients are also
worthy of attention [19,20]: renin–angiotensin–aldosterone sys-
tem (RAAS) blockers have been suspected to facilitate intracellular
penetration of SARS-CoV-2 [21]; and dipeptidyl peptidase (DPP)-4
inhibitors can interfere with the immune response [22].
Thus, identifying the risk factors of progression to serious life-
threatening COVID-19 infection is a key step that would allow
preventative strategies in the diabetes population to limit the
incidence of traumatic outcomes, such as the need for tracheal
intubation for mechanical ventilation or death.
Findings from CORONADO
The CORONADO (Coronavirus SARS-CoV-2 and Diabetes Out-
comes) study was a large-scale nationwide (68 French centres)
observational study of patients with diabetes hospitalized for
COVID-19 carried out in March 2020 [23]. Its main objective was to
identify the clinical and biological characteristics associated with
disease severity and mortality in patients with diabetes in hospital
because of COVID-19. The primary outcome combined tracheal
intubation for mechanical ventilation and/or death within 7 days
of hospital admission. Individual components of the primary
outcome were considered a pre-specified secondary outcome, as
was also hospital discharge by day 7.Please cite this article in press as: Scheen AJ, et al. Prognostic factors in
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focused on 1317 participants (admitted during 10–31 March
2020 at 53 centres) who were predominantly T2D patients (88.5%),
with a gender distribution of 35% female vs. 65% male. Their mean
age was 69.8 years and median body mass index (BMI) was
28.4 kg/m2. Microvascular (including chronic kidney disease) and
macrovascular complications were found in 46.8% and 40.8% of
patients, respectively, and a medical history of hypertension was
identified in 77.2% (57.1% were using RAAS inhibitors). Their mean
glycated haemoglobin (HbA1c) level was 8.1  1.9% (65  21 mmol/
mol), and their routine glucose-lowering medications mostly
comprised metformin (56.6%), insulin therapy (38.3%) and DPP-4
inhibitors (21.6%).
The composite primary outcome was noted in 29.0% of
participants, while 10.6% died and 18% were discharged by day
7. Whereas, on univariate analyses, several characteristics at
admission were significantly associated with the primary outcome
(higher BMI, male gender and previous treatment with RAAS
blockers, the latter two of only borderline significance), on
multivariable analyses, only BMI remained positively associated
with the primary outcome [odds ratio (OR): 1.28; 95% confidence
interval (CI): 1.10–1.47]. Of note, however, this association was
largely driven by tracheal intubation rather than death. Moreover,
the increased risk of the primary outcome appeared to be less in
patients with grade-3 obesity (BMI  40 kg/m2) than in those who
were overweight (25–29.9 kg/m2) or with grade 1–2 obesity (BMI
30–39.9 kg/m2).
It was also noteworthy that age, history of microvascular and
macrovascular complications, decreased estimated glomerular
filtration rate (eGFR) and comorbidities such as treated obstructive
sleep apnoea were all independently associated with risk of death
by day 7 (OR: 2.14–2.80). Age played a major role (OR: 14) when
diabetes patients > 75 years of age were compared with diabetes
patients < 55 years of age. Previous long-term glucose control, as
assessed by HbA1c measurement, was not significantly associated
with the primary outcome, unlike early clinical (dyspnoea) and
biological [elevated C-reactive protein (CRP)] markers of more
severe disease. In fact, in age- and gender-adjusted non-linear
models, plasma glucose concentrations at admission were
significantly and positively associated with both the primary
outcome and death by day 7. However, the negative impact of
admission ambient glucose concentrations was no longer signifi-
cant on multivariate analysis. It is also worth noting that diabetes-
related disorders with severe hyperglycaemia, including ketosis
and ketoacidosis, and also hypoglycaemic events were reported at
the time of admission. patients with diabetes hospitalized for COVID-19: Findings from
20), https://doi.org/10.1016/j.diabet.2020.05.008
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the prognosis for COVID-19 infection in people with diabetes, as
20.3% of the study population required tracheal intubation for
mechanical ventilation, and the mortality rate was 10.6% as early
as 7 days after admission. On multivariate analysis, an increased
BMI (already starting in the overweight range) was the only
independent prognostic factor of COVID-19 severity, as assessed by
the composite primary outcome in this large cohort of diabetes
patients. Of major importance, however, having a history of
vascular diabetes complications and treated obstructive sleep
apnoea significantly increased the risk of death. In contrast,
parameters of previous or admission glucose control and routine
pharmacological therapies, including RAAS blockers and DPP-4
inhibitors, were not independently associated with such a
prognosis.
Unanswered questions
At this time, CORONADO is the largest published observational
study specifically focused on the characteristics of diabetes
patients hospitalized for COVID-19 infection. It was designed to
address three main objectives:
 to characterize the phenotype of patients with diabetes
hospitalized for COVID-19;
 to determine the prevalence of poor prognoses using a primary
outcome combining death and tracheal intubation for mechani-
cal ventilation within the first 7 days of hospital admission; and
 to identify any prognostic factors associated with early severity
of COVID-19 in this specific in-patient diabetes population, a key
step towards implementing preventative strategies to reduce
the risk of life-threatening outcomes.
However, numerous factors may interfere with the relationship
between COVID-19 infection and poor outcomes in patients withFig. 1. Factors that may have an impact on outcomes of COVID-19 (Coronavirus Disease
Diabetes Outcomes (CORONADO) study and others. RAAS: renin–angiotensin–aldoste
apnoea; NAFLD: non-alcoholic fatty liver disease.
Please cite this article in press as: Scheen AJ, et al. Prognostic factors in
the CORONADO study and other recent reports. Diabetes Metab (20diabetes (Fig. 1). The present discussion focuses only on the three
that merit particular interest and which mostly concern patients
with T2D, who represented 88.5% of patients included in the
CORONADO study [23]. The number of patients with type
1 diabetes (T1D) was deemed too small from which to draw any
definite conclusions in this patient subgroup.
Role of diabetic complications and glucose control
Although vascular diabetic complications did not significantly
influence the composite primary outcome, they were significantly
associated with death in the CORONADO cohort [23]. This is not
surprising, as it is well established that both CVD and renal
impairment are associated with higher death rates in the diabetes
population in both long-term and acute conditions, such as those
encountered with severe COVID-19 infection [14]. In addition,
besides causing severe pneumonia, it is well known that the SARS-
CoV-2 coronavirus can induce cardiovascular complications [8,24]
and acute renal injury [25,26], making it highly plausible that these
detrimental complications are likely to be more frequent and
severe in such predisposed patients.
One question of interest is the potential role of glucose control
on outcomes related to COVID-19 in patients with diabetes. This
crucial point should be analyzed according to three separate
periods:
 prior to admission (assessed by HbA1c measurement);
 at the time of hospital admission (indicated by concomitant
plasma glucose concentrations); and
 during the hospital stay (Fig. 1).
An important message of the present results of CORONADO is
that previous glucose control has no significant impact on severity
of COVID-19 in people with diabetes who require hospitalization.
Indeed, HbA1c levels were associated with neither the composite 2019) infection in patients with diabetes as per the Coronavirus SARS-CoV-2 and
rone system; DPP-4is: dipeptidyl peptidase-4 inhibitors; OSA: obstructive sleep
 patients with diabetes hospitalized for COVID-19: Findings from
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surprising as chronic hyperglycaemia has long been known to
damp down the immunological defences of diabetes patients
[18,27]. However, caution is still required, as HbA1c measurements
were missing in about one-third of the studied population. Thus, it
would appear to be most prudent to wait for the final analysis of
CORONADO in an even larger cohort before drawing any definite
conclusions as to the role of patients’ past glucose control on final
outcomes. Moreover, as CORONADO was focused on hospitalized
patients with diabetes, it is still not known whether poor glucose
control might favour the occurrence of less severe COVID-19
infection in diabetes patients not requiring hospitalization.
Similarly, while plasma glucose concentration at admission was
not significantly correlated with the primary outcome on
multivariate analysis, in age- and gender-adjusted non-linear
models, admission plasma glucose concentrations were signifi-
cantly and positively associated with both the primary outcome
and death by day 7. Nevertheless, this observation relied upon only
one glucose measurement, which was not performed under
standardized conditions across all study patients (for example,
venous vs. capillary glucose, fasting vs. postprandial, variable time
delay from last administration of glucose-lowering medication,
especially insulin . . .). Thus, here again, caution is required in the
interpretation of these data. It may be speculated that, at least in
some patients, acute hyperglycaemia at admission could be linked
to disease severity and stressful conditions, especially if hypoxia
and respiratory distress (dyspnoea at hospital admission was
associated with the primary outcome) were already present. Thus,
plasma glucose at admission could be considered an early marker
of disease severity.
Also of potential interest, it was previously reported that the
SARS coronavirus may be able to enter pancreatic islets through its
ACE2 receptor, thereby causing damage to beta cells and leading to
acute diabetes [28]. However, whether or not there is a reverse
causality relationship between COVID-19 infection and acute
hyperglycaemia remains speculative, as this question cannot be
answered by any observational study (such as CORONADO).
One important aspect not considered at all in the CORONADO
study was the management of diabetes and quality of glucose
control during hospitalization (from admission to day 7). Attention
to good glucose control was recently recommended [29] and
demonstrated in a large study of 7337 cases of COVID-19 (of which
952 had preexisting T2D) [30]. In that retrospective observational
study from China, patients with well-controlled blood glucose
(range: 3.9–10.0 mmol/L) during hospitalization experienced
markedly lower mortality compared with those with poorly
controlled blood glucose [upper limit of glycaemic variabili-
ty: > 10.0 mmol/L; adjusted hazard ratio (HR): 0.14, 95% CI: 0.03–
0.60; P = 0.008]. Previous studies done before the COVID-19
pandemic had shown that the quality of glucose control during
hospitalization in ICUs for an acute event (cardiovascular surgery,
myocardial infarction . . .) could influence the final outcome,
although controversial results were reported concerning optimal
target levels of glycaemia [31,32]. Nevertheless, there is some
consensus for maintaining blood glucose concentrations at 4–
10 mmol/L in diabetes patients hospitalized in ICUs as well as in
those now with COVID-19 [33].
However, even if the impact of glucose control during the
hospitalization of diabetes patients with COVID-19 has yet to be
prospectively investigated, the need for diabetes care customized
for ICUs has been strongly suggested to help healthcare providers
who are already overwhelmed by the dramatic pandemic situation
and the need to support other vital functions, thereby potentially
exposing patients with diabetes to poorer management of their
specific disease [34]. Likewise, it has also been suggested that
individualized care strategies, novel therapeutic regimens and thePlease cite this article in press as: Scheen AJ, et al. Prognostic factors in
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clinical inertia hampering proper diabetes management in ICUs, a
situation that could lead to poor glucose control and potentially
worse outcomes for patients with diabetes and COVID-19 infection
[35].
In fact, diabetes patients with COVID-19 have to control their
glucose levels in a situation with more variable, and often
decreased, food intakes, while also being confronted with a severe
infection generally accompanied by fever and a cytokine-mediated
insulin-resistant state. In addition, as already mentioned, it is also
possible that the SARS coronavirus can penetrate into pancreatic
islets and damage beta cells, thereby aggravating the course of
diabetes and triggering acute hyperglycaemia [28]. Thus, COVID-
19 represents a double threat to patients with diabetes. The
difficulty of controlling diabetes in such a setting has been
confirmed by, on the one hand, the rather large number of
ketoacidosis episodes already reported [36] and, on the other hand,
the episodes of hypoglycaemia most probably due to an unantici-
pated lack of food, two metabolic adverse events reported at
hospital admission in the CORONADO cohort [23].
Role of antihypertensive and antidiabetic medications
Many patients with diabetes are treated with RAAS blockers as
either antihypertensive agents or for nephroprotection. In the
CORONADO study, 57.1% of the diabetes cohort received such
pharmacotherapy. Yet, there has been some controversy in the
literature over the possible negative, neutral or even positive
impact of RAAS blockers on risk associated with these medications
when administered to COVID-19 patients [20,37,38]. However,
CORONADO has provided reassuring results, as RAAS blockers
were not associated with the primary outcome according to
multivariable analysis [23]; these observations are in agreement
with the results of other studies [21,39,40] and support the
recommendation not to stop RAAS blockers in diabetes patients
possibly exposed to SARS-CoV-2 infection [41]. Also, as discussed
by the authors, the negative impact of diuretics reported in the
study could be attributed to the more severe baseline condition of
patients suffering from heart failure or more severe hypertension.
The final question is whether or not glucose-lowering
medications could differentially affect the risk of COVID-19
infection and more severe outcomes [42,43], although there are
still many uncertainties in seeking answers [19]. A similar concern
as that discussed with RAAS blockers has been raised over the use
of DPP-4 inhibitors [20,22], although no worse signs were reported
among the 21.6% of patients treated with such agents in the
CORONADO cohort. The increased risk associated with insulin was
probably due to the fact that the use of this pharmacotherapy
reflects more advanced diabetes disease in patients who are often
older and more frail [44]. The possible protective role of metformin
has been proposed based on theoretical grounds, and the
pleiotropic effects of the compound have yet to be investigated
in clinical practice [45]. Of note in CORONADO, however, fewer of
the people who died were using metformin. It has also been
hypothesized that dapagliflozin (not available in France until only
recently) can prevent the severe course of COVID-19 infection by
preventing the lowering of cytosolic pH and reducing the viral load
[46]. A large international randomized controlled trial is currently
underway to investigate the potential role of dapagliflozin in both
diabetes and non-diabetes patients with COVID-19 ( Dapagliflozin
in Respiratory Failure in Patients with COVID-19; ClinicalTrials.gov
identifier: NCT04350593). In ICUs, the proper use of insulin
therapy is, without question, the mainstay therapy [33]. Neverthe-
less, in view of the major interest raised by COVID-19 in the
diabetes population, it is anticipated that dedicated observational
studies, and possibly randomized controlled trials, will be designed patients with diabetes hospitalized for COVID-19: Findings from
20), https://doi.org/10.1016/j.diabet.2020.05.008
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negative influences of the available glucose-lowering agents in
patients with T2D when exposed to SARS-CoV-2 coronavirus [47].
Role of obesity
The frequent concurrence of both diabetes and obesity may
confound, or at least complicate, identification of the independent
role of either condition on its own. The negative effects of obesity
on the severity of COVID-19 [48] and the need for invasive
mechanical ventilation [49,50] have already been reported
independently of the presence of diabetes. In addition, the
CORONADO study has confirmed the deleterious role of obesity,
and even overweight, in life-threatening outcomes in a large
diabetic (mainly T2D) population with COVID-19 [23]. On
multivariate analyses, BMI remained the only prognostic factor
for the composite primary outcome. The negative impact of obesity
on outcome was largely driven by its effect on tracheal intubation
for mechanical ventilation whereas its effect on mortality was
considerably lower. While death is an unequivocal outcome,
mechanical ventilation depends on both the physician’s decision
and patient’s acceptance.
It remains unclear as to why obesity aggravates COVID-19
severity and markedly increases the need for tracheal intubation
for mechanical ventilation [49], although several underlying
mechanisms may be considered. Obese patients have impaired
respiratory mechanics resulting from a combination of poor
respiratory muscle strength, reduced lung volume, increased
airway resistance and impaired gas exchange. In addition, more
subtle yet complex interactions may arise between adipose tissue
and the immune system [48,51]. For instance, an overexpression of
inflammatory adipokines from visceral fat depots can affect the
immune response, impair chemotaxis and alter macrophage
differentiation [52]. In addition, the inflammatory response of
visceral, but also thoracic (epicardial and mediastinal), fat deposits
can lead to an upregulation and greater release of inflammatory
cytokines such as interleukin (IL)-6 [5]. It has been suggested that
adipose tissue in people with obesity may act as a reservoir for
more extensive viral spread and increased shedding, immune
activation and cytokine amplification [53]. Indeed, it has even been
hypothesized that excess fat might lead to the possible presence of
ectopic fat deposits in the alveolar interstitial space that is exposed
to viral infection. This, in turn, could aggravate the inflammatory
infiltrate, a phenomenon that could then contribute to the massive
oedema observed in COVID-19 patients who require mechanical
ventilation [50].
Moreover, obesity is associated with an increased risk of
comorbidities, such as hypertension, renal impairment, obstruc-
tive sleep apnoea [54] and non-alcoholic fatty liver disease
(NAFLD) [55], all conditions that can aggravate the prognosis
[14]. Of particular interest, in the CORONADO cohort, obstructive
sleep apnoea was found to be an independent risk factor of early
death, as were also elevated levels of aspartate transaminase (AST).
While a previous history of NAFLD was not associated with the
primary outcome, the elevated AST levels noted at admission may
have been a reflection of liver cytolysis directly due to SARS-CoV-2
infection [56] or related to multiple-organ damage secondary to
hypoxia, a systemic cytokine storm and/or haemodynamic shock
[14,57]. In fact, AST elevation has more frequently been observed in
severe forms of COVID-19 infection, especially during hospitaliza-
tion [56]. In a longitudinal retrospective cohort study of
5771 patients with COVID-19 in China, abnormal AST levels were
associated with the highest mortality risk compared with other
indicators of liver damage, with an HR of 4.81 with AST levels of
40–120 U/L and an HR of 14.87 when AST was > 120 U/L [58]. In a
meta-analysis of 13 studies involving a total of 3027 patients withPlease cite this article in press as: Scheen AJ, et al. Prognostic factors in
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4 for critical/fatal COVID-19 [12]. The findings of CORONADO are in
line with such observations.
Taking BMI into account even in a population with diabetes
might improve risk stratification, thereby allowing for more
effective selection of the diabetes patients who are most likely to
require early hospital admission and stricter safety measures to
minimize their increased risk of developing more severe compli-
cations. However, not all studies reported the same BMI cut-off in
association with greater risk of severe complications related to
COVID-19. In CORONADO, a higher risk had already been observed
in overweight patients with diabetes. However, an increased risk
for the primary outcome appeared to be less pronounced in
diabetes patients with grade-3 obesity (BMI  40 kg/m2). The
authors considered this observation to be in agreement with the
so-called ‘‘obesity paradox’’ previously reported in ICUs in patients
exposed to severe respiratory distress syndromes. Nevertheless,
researchers in a French study reported higher risks if BMI was
 35 kg/m2 [49], whereas one US study [59] reported an even
higher risk if BMI was  40 kg/m2 as did another large US study
[60] in cohorts of COVID-19 patients not specifically focused on
diabetes. In fact, it has been suggested that COVID-19 may be a
challenge to the ‘‘obesity paradox’’ [61], although more data from
patients with morbid obesity (BMI  40 kg/m2) are as yet required
to support this conclusion [48].
Thus, there is clearly a need for more evidence to raise
awareness of what BMI score should be considered the cut-off for
an increased risk of severe illness as a result of COVID-19 [62]. In
addition, whether such a cut-off might differ in patients with and
without diabetes also requires further investigation. In any case,
given the potentially critical role of body weight and fat mass in
determining the severity of pneumonia requiring respiratory
assistance, it is important to systematically collect anthropometric
information from patients hospitalized with COVID-19 [63]. One
noteworthy suggestion is that obesity could shift severe COVID-19
infections towards younger age groups [64,65]. Indeed, it may be
speculated that a similar shift occurred in patients with diabetes in
the CORONADO cohort (about one-third of whom were
aged < 65 years), although direct comparison with a non-diabetes
population remains mandatory to confirm such an hypothesis.
Ultimately, if obesity plays a crucial role, then therapeutic
actions targeting adipose tissue could help to reduce the burden of
COVID-19 disease, including in the large cohort of patients with
T2D [51]. Likewise, if adipose tissue related to obesity plays a
deleterious role in the excessive immune reaction and inflamma-
tion, then diabetes patients with obesity might benefit to a greater
extent from a pharmacological therapy that modulates cytokine
activity, especially IL-6, and/or the complement system [50]. As
such, tocilizumab has been proposed as a therapeutic option for
compassionate use in patients with COVID-19 [66]. A recent
observation has found that hyperglycaemia, both at admission and
during the hospital stay, was associated with higher IL-6 levels and
a reduced efficacy of tocilizumab, leading to poorer outcomes in
COVID-19 patients regardless of the presence or not of known
diabetes [67]. However, further studies are now necessary to
confirm this finding.
Conclusion
Diabetes is one of the more important comorbidities linked to
the severity of infection by SARS-CoV-2. The CORONADO study was
designed to characterize the phenotype of patients with diabetes
hospitalized for COVID-19, to determine the prevalence of the need
for mechanical ventilation or death and to identify the prognostic
factors associated with poorer outcomes. As the first such patients with diabetes hospitalized for COVID-19: Findings from
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major piece of the complex puzzle linking diabetes and COVID-19
infection: some prognostic factors have been identified, focusing
on BMI in relation to the need for respiratory assistance and the
presence of previous diabetes complications associated with risk of
death. However, other answers still require further analyses in
even larger cohorts, especially in order to reassess the influence of
previous glucose control based on larger numbers of HbA1c
measurements, which means that the final results of the
CORONADO study are awaited with great interest. In addition,
the impact of glucose control during hospitalization on outcomes
related to COVID-19—which was not investigated in CORONADO—
is certainly deserving of specific investigation. Moreover, the
results of certain pharmacological therapies currently under
investigation to improve the prognosis in high-risk populations,
such as diabetes patients, are also likely to be available in the near
future.
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